Piperidine Urea Derivatives for Obesity Therapy Patent Application
Summary
The USPTO has published a patent application (US20260083718A1) filed by Astrizi Bio, Inc. The application describes piperidine urea derivatives for preventing, suppressing, or treating obesity, potentially in combination with GLP-1 receptor agonists.
What changed
This document is a published patent application from the USPTO for "Piperidine urea derivatives for obesity therapy." The application, filed by Astrizi Bio, Inc., details methods and compositions involving select piperidine urea-derived compounds for treating obesity, either as a monotherapy or in combination with GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists.
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in obesity therapeutics and may be of interest to pharmaceutical companies and researchers in the field for competitive intelligence and R&D planning.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY
Application US20260083718A1 Kind: A1 Mar 26, 2026
Assignee
Astrizi Bio, Inc.
Inventors
Ish Khanna, Sivaram Pillarisetti, Hans Marcus Malkmus, Kathrin Christin Kortschak
Abstract
The subject matter disclosed herein is generally directed to methods and compositions for preventing, suppressing or treating obesity and/or obesity-induced disorders, specifically, select piperidine urea-derived compounds as a monotherapy or a combination therapy with glucagon-like peptide 1 (GLP-1—SEQ ID NO: 1) receptor agonist and/or dual GLP-1 (SEQ ID NO: 1) and glucose-dependent insulinotropic polypeptide GIP (SEQ ID NO: 8) receptor agonist for the treatment of obesity.
CPC Classifications
A61K 31/4545 A61K 31/497 A61K 31/506 A61P 3/04
Filing Date
2025-09-24
Application No.
19338129
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.